Statistics from Altmetric.com
Dolutegravir is a substrate of UGT1A1 and CYP3A4, both of which are induced by rifampicin.1 Coadministration with rifampicin results in decreases in dolutegravir plasma exposure, requiring doubling of the daily dose of dolutegravir.1 Preliminary results of a phase III study (INSPIRING) evaluating the safety of dolutegravir use (50 mg twice daily) in combination with rifampicin were recently presented at the Conference on Retroviruses and Opportunistic Infections.2 At 24 weeks, 81% (56/69) of HIV/TB …
Contributors MC and HM have planned the audit. MC generated and analysed the data, and drafted the first manuscript. Both authors contributed to the final manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.